Editorial In this issue of AMPS-QT, we proudly introduce Dr.

University of California, San Francisco since 1998. Dr. Iribarren is a clinical epidemiologist and his current research interests include the genetic basis of coronary disease, biomarkers of atherosclerosis and psychosocial factors in coronary disease. Dr. Iribarren’s ECG research studies are an excellent illustration of how AMPS technology can be used effectively beyond the pharmaceutical borders. Indeed, Dr. Iribarren is an active clinical epidemiologist with primary interests in characterizing electrocardiographic features such as the QT interval in very large populations, a context where AMPS software solutions can be very handy and useful. In one of his recently published contributions, Dr. Iribarren and his colleagues focused on the drug-induced alterations of QT interval in 59,467 subjects undertaking a comprehensive list (n=90) of selected drugs used as part of routine clinical practice and using the AMPS resting ECG tool CalECG to validate their methodology [1,2]. We have asked Dr. Iribarren to give us an overview of his findings which, we are sure, all our readers will greatly enjoy